Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 8 sources · 23 days · First seen about 1 month ago · Last updated 8 days ago

Samsung Biologics biopharmaceutical manufacturing expansion

Overview

Samsung Biologics has been presenting its contract development and manufacturing organization (CDMO) capabilities and technological innovations at international industry conferences.

In late September 2026, the company showcased its end-to-end manufacturing strategies at the BioProcess International conference in Boston. Highlights included the ‘S-Tensify’ platform for increasing cell density and integrated chemistry, manufacturing, and controls (CMC) processes designed to reduce development timelines. The company also shared analytical strategies for adeno-associated virus (AAV) products.

By October 2026, the focus shifted toward specialized modalities at the World ADC San Diego conference. Samsung Biologics highlighted its integrated services at its Songdo facility, which include Contract Research (CRO), Contract Development (CDO), and Contract Manufacturing (CMO). Following the launch of a dedicated Antibody-Drug Conjugate (ADC) production facility in March 2025, the company aims to establish a full-cycle drug product line by 2027. Additional technical advancements presented included the S-DUAL bispecific antibody platform and the Samsung Organoids platform for drug screening.

Entities

Samsung Biologics · Songdo · World ADC San Diego 2026 · Samsung Organoids · Marc Studer

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] Samsung Biologics participated in the World ADC San Diego 2026 conference.
[● 3 SOURCES] The company provides end-to-end services including CRO, CDO, and CMO for Antibody-Drug Conjugates (ADC).
[● 3 SOURCES] Samsung Biologics launched its dedicated ADC production facility in March 2025.
[● 3 SOURCES] The company utilizes its S-DUAL bispecific antibody platform for ADC development.
[● 3 SOURCES] The company offers drug screening services using patient-derived organoids (PDO) via Samsung Organoids.
[● 2 SOURCES] The company plans to establish and operate a dedicated ADC drug product (DP) line by 2027.

Timeline

8 days ago

[BUSINESS] 4 sources
Samsung Biologics showcases end-to-end ADC service capabilities
Samsung Biologics presented its end-to-end ADC CDMO capabilities at World ADC San Diego 2026, highlighting its integrated CRO, CDO, and CMO services and plans for a dedicated drug product line by 2027.
about 1 month ago

[BUSINESS] 6 sources
Samsung Biologics showcases manufacturing innovations at BPI Boston
Samsung Biologics showcased advanced CDMO technologies and faster drug manufacturing timelines at the BPI conference in Boston, while Shaperon introduced a new NDC platform to simplify drug conjugation.

Sources

biz.heraldcorp.com · kgnews.co.kr · koreaherald.com · kyeonggi.com · m.koreatimes.co.kr · m.sportalkorea.com · techholic.co.kr · thebionews.net